If you’re on a weight loss journey, you now have an arsenal of medications at your disposal. And while injectable medications have dominated the space for years, GLP-1 weight loss pills are now on the table. Two options are now available: Wegovy (semaglutide) or Foundayo (orforglipron). To make an informed decision, it is essential to understand the characteristics of each medication with the help of a healthcare professional.
The Wegovy pill, made by Novo Nordisk, is an FDA-approved oral semaglutide medication for adults with overweight or obesity. It is designed to be taken in smaller doses before increasing to a larger dose. Tony Yang, DSc, MPH, professor at the Milken Institute School of Public Health, notes that semaglutide has a long real-world track record, and physicians have experience managing its side effects and dosing nuances.
How the Medications Work
The Wegovy pill works by mimicking a protein called glucagon-like peptide 1 (GLP-1), reducing hunger and slowing down food transit in the gut. It is taken once a day on an empty stomach with up to four ounces of water, and users must wait 30 minutes before eating or taking other medications.
Foundayo, made by Lilly, is also a GLP-1 medication that mimics the hormone released after eating, signaling the brain that it’s time to stop. Dr. Yang explains that Foundayo’s small molecule structure allows it to pass through the gut intact, regardless of food intake, making it more convenient than peptide-based GLP-1s like semaglutide.
Related Post: Priority Life Care Acquires Seven, Janus Boosts Credit
Both medications have undergone extensive clinical trials, with similar weight loss results: adults on Foundayo lost an average of 27 pounds or 12.4% of their body weight over 72 weeks, while those on Wegovy lost an average of 33 pounds or 14% of their body weight over 64 weeks.
A comparison of the two medications by Novo Nordisk found that people on the Wegovy pill had significantly greater weight loss than those on Foundayo. However, this was an indirect treatment comparison, not a head-to-head randomized controlled trial, and the results should be interpreted with caution. A Lilly spokesperson notes that indirect cross-trial comparisons are hypothesis-generating but not a replacement for gold-standard randomized head-to-head clinical trials.
Doctors stress that both medications can be helpful for patients, and the choice between them depends on individual factors, such as lifestyle and personal preferences. Dr. Arora recommends considering the oral Wegovy pill for those who thrive on structure and want to maximize weight loss, while Foundayo may be more suitable for individuals with varying schedules or those who struggle with complicated dosing rules.
The side effects of both medications are similar, with some overlap. Both medications list potential side effects such as burping, constipation, diarrhea, fatigue, and nausea. Foundayo may cause additional side effects like hair loss and indigestion, while the Wegovy pill may cause dizziness, feeling bloated, and low blood sugar in people with type 2 diabetes.
When choosing between the two medications, doctors advise patients to consider their personal goals and what matters most to them. Dr. Giaquinto notes that it is essential to stop thinking about what might be “best” overall and instead focus on individual needs and circumstances. Ultimately, the decision should be made after an honest conversation with a healthcare provider, taking into account the patient’s lifestyle, medical history, and personal preferences.
Related Post: Health systems adapt for future care needs
While the Wegovy pill must be taken on an empty stomach with limited water intake, Foundayo can be taken without restrictions around meals or water. The FDA has approved Foundayo for doses up to 17.2 milligrams, although Novo Nordisk notes this is equivalent to the 36-milligram capsules used in phase 3 clinical trials.
Medication Adherence
Dr. Yang emphasizes that the best medication is the one that people will actually take consistently, and the convenience of Foundayo may make it a more attractive option for some patients.
Initiation Dosing, Molecular Differences and Trial Comparisons
Foundayo treatment begins with a low dose that is gradually increased to the target amount. Orforglipron imitates the gut hormone that signals satiety after meals. Unlike peptide-based GLP-1 agents, which degrade in stomach acid and have historically required injections or strict fasting protocols for oral forms, the small-molecule composition remains stable through digestion.
In a recent Novo Nordisk press release, a 25-mg Wegovy pill dose was compared with a 36-mg Foundayo dose used in phase-3 trials. The report indicated that Wegovy participants achieved significantly greater weight loss, while Foundayo users were roughly four times more likely to discontinue because of side effects. The analysis combined data from separate studies, adjusted for baseline weight, glycemic status and sex, and was conducted by the Wegovy maker.
